Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00141050Phase 3Completed
Phase 3, randomised, double-blind trial of dexmethylphenidate in attention deficit hyperactivity disorder (ADHD) (5 arms), sponsored by Novartis. Primary endpoint: Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Score. Started May 2005; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00141050.